JMP Securities analyst Reni Benjamin raised the firm’s price target on Kura Oncology to $32 from $22 and keeps an Outperform rating on the shares. Kura provided a data from the first 20 patients of the KOMET-007 trial, with the data showing promising efficacy and safety that have potential to be best-in-class as higher doses are explored, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KURA:
- Kura Oncology’s KOMET-007 Trial Shows Promising Results
- Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
- Kura Oncology to hold a virtual investor event
- Kura Oncology Announces Private Placement Details
- Kura Oncology Executes Unregistered Equity Securities Sale
